Navigation Links
MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
Date:10/31/2007

MOUNTAIN VIEW, Calif., Oct. 31 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, today announced the initiation of a Phase 2a clinical trial evaluating MAP0005 for the potential treatment of asthma and chronic obstructive pulmonary disease (COPD).

MAP0005 is a combination of a corticosteroid and a long-acting beta2-agonist delivered to the respiratory tract using MAP Pharmaceuticals' Tempo(TM) inhaler. MAP0005 uses the Company's proprietary particle technology to combine the corticosteroid and beta-agonist components into a single drug particle in a fixed, pre-specified ratio. In addition, MAP Pharmaceuticals' technology allows for the particle structure to be specifically designed to target relevant areas in the lung and to release drug at a desired rate. MAP Pharmaceuticals believes that this approach may enable the reproducible and consistent administration of the two drugs in an optimal ratio simultaneously, and may provide improved safety and efficacy over currently available combination therapies for asthma and COPD.

"By combining drugs at the micron or submicron particle level, rather than as separate particles, as practiced with current inhaled combination therapies, we can potentially enhance the synergistic effect of the drugs and increase dosing efficiency and consistency," said Thomas A. Armer, Ph.D., founder and Chief Scientific Officer of MAP Pharmaceuticals. "Furthermore, the novel technology we apply to MAP0005 is potentially applicable to a broad range of combination drug products, for a variety of indications and routes of administration, such as oral administration."

"The initiation of our Phase 2a trial is an important step for
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... DC (PRWEB) May 20, 2013 Medicare ... are overwhelmingly satisfied, citing lower costs, convenient access to ... from Hart Research Associates released today by the Pharmaceutical ... D seniors (9.5 million) are currently enrolled in plans ... pharmacy choices, and overall value of plans with preferred ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 A new ... by MedEx Direct, the creators of the MedEx Pack ... the Benefits of Pharmacy Home Delivery, in order to provide ... their prescriptions are handled. Clyde Furuta, MedEx Direct owner ... home delivery is that with a product like the MedEx ...
(Date:5/20/2013)... improved health care and significant reductions in drug costs ... between physicians and drug company representatives who promote the ... This system, which has been in place for decades, ... to date on new medications, and always provided generous ... the newest drugs, as well as other supplies and ...
(Date:5/20/2013)... T.E.N. announced today that it would ... Security Executive® Northeast Awards now through Friday, July ... Security Executive® of the Year and ISE® People’s ... a positive impact on their organizations through risk ... security; and the ISE® Project of the Year, ...
(Date:5/20/2013)... Geneva, Switzerland (PRWEB) May 20, 2013 ... discovery for lead identification and cell line development for ... that the Company’s co-founder will present data on the ... Development & Engineering Conference, May 20 - 23 ... La Jolla, California. Selexis’ co-founder and scientific advisory board ...
Breaking Medicine News(10 mins):Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2Health News:Benefits of Pharmacy Home Delivery Report Published by MedEx Direct 2Health News:Breakup of physician, drug company relationship could improve health care, cut cost 2Health News:Breakup of physician, drug company relationship could improve health care, cut cost 3Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 2Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 3Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 2Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 3
... Children, WASHINGTON, Oct. 3 Campaign for ... veto of the,Children,s Health Insurance Program Reauthorization bill ... nation,s broken health care systems. The bill,the president ... for 6.6 million children and provide coverage to ...
... Information,Systems, Inc., (Nasdaq: MEDW ) announced that ... the company regarding the company,s,non-compliance with Nadsaq Marketplace ... company,s audit committee. This issue arose,due to the ... an audit,committee member. On October 2, 2007, ...
... say , WEDNESDAY, Oct. 3 (HealthDay News) -- Identifying ... the best chemotherapy for patients, U.S. research suggests. , ... most likely to respond to standard first-line therapy and ... a second-line therapy, based on gene expression profiling," lead ...
... outcomes for high-risk patients , , WEDNESDAY, Oct. 3 (HealthDay ... the bare-metal kind for high-risk patients with blocked coronary ... of restenosis -- having the artery become blocked again ... following two years for those getting drug-coated stents, 7.4 ...
... Oct. 3 Abaxis, Inc.,(Nasdaq: ABAX ), ... systems, announced today the launch of the Kidney,Check ... Piccolo xpress(TM) point of,care analyzer. The new ... and,radiology centers in the United States to determine ...
... Nowhere are the,consequences of premature birth more evident than ... the next week, 563 babies,will be born too soon ... watch their babies be admitted into a NICU. Having ... the most frightening and overwhelming,experiences a parent faces. ...
Cached Medicine News:Health News:Mediware Information Systems, Inc. Receives Notice from the Nasdaq Stock Market 2Health News:Gene Tests Match Up Lung Tumors, Best Treatment 2Health News:Study Finds Benefits With Drug-Coated Stents 2Health News:Study Finds Benefits With Drug-Coated Stents 3Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 3Health News:March of Dimes NICU Family Support(R) Programs Give Florida Families Comfort and Information During a Crisis 2
(Date:5/20/2013)... 2013 /PRNewswire-iReach/ -- Today at American Society for ... Ginocchio discussed Specific Technologies blood culture ... of microorganisms producing bloodstream infection. Dr. Ginocchio is ... Division of Infectious Disease Diagnostics at North Shore-LIJ ... health system. (Photo: http://photos.prnewswire.com/prnh/20130520/CG16829 ) ...
(Date:5/20/2013)... Calif. , May 20, 2013 /PRNewswire-iReach/ -- ... of the first study demonstrating detection of pathogenic ... Yersinia pestis and Bacillus anthracis ... and Prevention,s list of potential bio-threats. This seminal ... and Technology Laboratory, Salisbury ...
(Date:5/20/2013)... , May 20, 2013  Hill-Rom Holdings, Inc. (NYSE: ... a management presentation at the 38 th Annual ... on May 30, 2013, at 1:30 p.m. ... You are invited to listen to the live ... or access it directly at http://www.media-server.com/m/p/f7bj3q84 . A ...
Breaking Medicine Technology:Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3Specific Technologies Detects and Identifies Potential Bioterrorism Pathogenic Bacteria 2
... 7, 2011 Rochester Medical Corporation (NASDAQ: ... the previously announced purchase of Laprolan B.V., the former ... BioSciences N.V. Under the terms of the purchase agreement ...  For more information regarding this transaction please refer to ...
... April 7, 2011 Ascension Orthopedics, Inc., a world ... the TITAN Modular Total Shoulder.  The surgeries were performed ... Baltimore, MD.     "I have been ... of years in my practice. Now that Ascension has ...
Cached Medicine Technology:Ascension Orthopedics Announces TITAN™ Modular Shoulder Implantations at Union Memorial Hospital 2
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
The Oxoid Legionella Latex Test is a latex agglutination test for the identification of predominant Legionella species grown on plate media from patients with suspected Legionellosis or from environm...
Inquire...
Medicine Products: